This is a summary of the European public assessment report (EPAR) for Hexacima. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Hexacima. For practical information about using Hexacima, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Hexacima (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). The use of this vaccine should be in accordance with official recommendations.
Therapeutic Area (MeSH)
N/AATC Code
J07CA09
ATC Item
diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
N/AINN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| hepatitis B surface antigen | N/A | 乙型肝炎病毒表面抗原 |
| Diphtheria toxoid | N/A | 白喉类毒素 |
| tetanus toxoid | N/A | 破伤风类毒素 |
| Bordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutinin | N/A | Bordetella pertussis toxoid antigen (formaldehyde inactivated) |
| poliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett) | N/A | inactivated poliovirus vaccine |
| Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein | N/A | haemophilus influenzae type b |
EMA Name
Hexacima
Medicine Name
Hexacima
Aliases
N/ANo risk management plan link.
